论文部分内容阅读
目的:研究雌激素受体(ER)、孕激素受体(PR)和c-erbB-2在乳腺癌原发灶和同期腋淋巴结转移灶之间的表达差异。方法:免疫组织化学方法检测60例初治单侧乳腺癌同期腋窝淋巴结转移手术治疗患者ER、PR和c-erbB-2在原发灶及腋淋巴结转移灶的表达差异。结果:ER在乳腺癌原发灶中的阳性率为56.7%(34/60),腋淋巴结转移灶中为48.3%(29/60);PR在乳腺癌原发灶中的阳性率为55.0%(33/60),腋淋巴结转移灶为48.3%(29/60);c-erbB-2在乳腺癌原发灶中的阳性率为26.7%(16/60),腋淋巴结转移灶为28.3%(17/60);ER、PR和c-erbB-2的阳性率在两者之间的差异均无统计学意义。ER在原发灶和腋窝淋巴结转移灶之间总的变化率为21.7%(13/60),PR为16.7%(10/60),c-erbB-2为15.0%(9/60)。结论:ER、PR和c-erbB-2的表达在乳腺癌原发灶和腋窝淋巴结转移灶之间存在不一致现象,但无统计学意义。判断乳腺癌的预后要综合考虑其原发灶和转移灶的生物学特性。
OBJECTIVE: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and c-erbB-2 in primary breast cancer and axillary lymph node metastases in breast cancer. Methods: Immunohistochemistry was used to detect the expression of ER, PR and c-erbB-2 in primary and axillary lymph node metastases in 60 patients with newly diagnosed unilateral breast cancer with axillary lymph node metastasis. Results: The positive rate of ER in primary breast cancer was 56.7% (34/60) and that in axillary lymph node metastasis was 48.3% (29/60). The positive rate of PR in primary breast cancer was 55.0% (33/60), and axillary lymph node metastasis was 48.3% (29/60). The positive rate of c-erbB-2 in primary breast cancer was 26.7% (16/60) and that of axillary lymph node metastasis was 28.3% (17/60). There was no significant difference in the positive rates of ER, PR and c-erbB-2 between the two groups. The overall rate of change of ER between primary and axillary lymph nodes was 21.7% (13/60), PR was 16.7% (10/60), and c-erbB-2 was 15.0% (9/60). CONCLUSIONS: The expressions of ER, PR and c-erbB-2 are not consistent between breast cancer and axillary lymph node metastases, but not statistically significant. To determine the prognosis of breast cancer to consider the biological characteristics of its primary and metastatic lesions.